NYSE:PENMedical Equipment
How STORM-PE Thrombectomy Results and Lightning Flash Data Will Impact Penumbra (PEN) Investors
Penumbra, Inc. recently reported 90-day results from its STORM-PE randomized trial, showing that computer assisted vacuum thrombectomy plus anticoagulation produced greater functional improvement and comparable safety versus anticoagulation alone in acute intermediate-high risk pulmonary embolism, based on data presented at the Society of Interventional Radiology Annual Scientific Meeting.
The trial’s first-of-its-kind data, alongside ongoing STRIKE-PE real-world outcomes research, positions...